Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3

Nadège Gaborit, Moshit Lindzen, Yosef Yarden

Open source

DOI
10.1080/21645515.2015.1102809
Published
2015-11-18
Container
Human Vaccines & Immunotherapeutics
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/21645515.2015.1102809,
  title = {Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3},
  author = {Nadège Gaborit and Moshit Lindzen and Yosef Yarden},
  year = {2015},
  journal = {Human Vaccines \& Immunotherapeutics},
  doi = {10.1080/21645515.2015.1102809},
  url = {https://doi.org/10.1080/21645515.2015.1102809}
}

RIS

TY  - JOUR
TI  - Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3
AU  - Nadège Gaborit
AU  - Moshit Lindzen
AU  - Yosef Yarden
PY  - 2015
JO  - Human Vaccines & Immunotherapeutics
DO  - 10.1080/21645515.2015.1102809
UR  - https://doi.org/10.1080/21645515.2015.1102809
ER  - 

APA

Gaborit, N., Lindzen, M., & Yarden, Y. (2015). Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2015.1102809

Source records